Research Papers:

Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer

Seok-Jun Kim, Jung-Ah Hwang, Jae Y. Ro, Yeon-Su Lee and Kyung-Hee Chun _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2013; 4:1461-1471. https://doi.org/10.18632/oncotarget.1219

Metrics: PDF 3079 views  |   HTML 3438 views  |   ?  


Seok-Jun Kim1, Jung-Ah Hwang2, Jae Y. Ro3, Yeon-Su Lee2, and Kyung-Hee Chun1

1 Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea.

2 Cancer Genomics Branch, Division of Fusion Technology, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea.

3 The Methodist Hospital, Department of Pathology and Genomic Medicine, Weill Medical College of Cornell University, Houston, TX, USA.


Kyung-Hee Chun, email:

Keywords: Galectin-7, Gastric cancer, DNA hypermethylation, Epigenetic mechanisms.

Received: July 30, 2013 Accepted: August 18, 2013 Published: August 20, 2013


Gastric cancer is the second leading cause of cancer death and remains a major clinical challenge due to poor prognosis and limited treatment options. Therefore, the basic mechanisms underlying gastric tumorigenesis deserve investigation. Although regulation of the galactoside-binding lectin galectin-7 in cancer has been studied, its role in tumor formation and progression remains controversial. In this study, we investigated galectin-7 expression and its role in gastric cancer. Immunohistochemical staining using a tissue microarray of gastric cancer patients revealed significantly low expression levels of galectin-7 in malignant tissues compared with matched normal tissues, and decreased expression of galectin-7 in malignant tissues was associated with advanced TMN stage disease (p=0.034). Importantly, low expression of galectin-7 in normal tissues was associated with a poor survival rate (p=0.0561). Over-expression of galectin-7 in AGS gastric adenocarcinoma cells suppressed cell proliferation, migration, and invasion, whereas ablation of galectin-7 in KATO III gastric carcinoma cells reversed these properties. AGS cells that overexpressed galectin-7 could not form gastric tumors in xenografted mice. More than 70% hypermethylation was observed in 7 of 9 gastric cancer cell lines tested and 5-aza-cytidine treatment lowered galectin-7 expression by reducing methylation in 24 cancer cell lines from five different organ origins. We analyzed CpG islands in the galectin-7 genomic region and detected hypermethylation at +1566bp of exon 2, the predicted p53 binding region. DNA hypermethylation of this region was also detected in gastric cancer tissues from 20 patients. Taken together, our data indicate that galectin-7 has a tumor suppressive function, and that the gene is epigenetically modified by DNA methylation and significantly down-regulated in gastric cancer. Further study of galectin-7 regulation may lead to improved gastric cancer diagnosis and therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1219